et al. Clinical utility of circulating tumor cell count as a tool to chose between .rst line hormone therapy and chemotherapy for ERt HER2 metastatic breast cancer: Results of the phase III STIC CTC trial. Abstract GS3-07 and oral presentation. Forty-First Annual CTRC-AACR San Antonio Breast ...
et al. Clinical utility of circulating tumor cell count as a tool to chose between .rst line hormone therapy and chemotherapy for ERt HER2 metastatic breast cancer: Results of the phase III STIC CTC trial. Abstract GS3-07 and oral presentation. Forty...
This was a grade E recommendation (expert opinion), meaning that “[t]here is insufficient evidence or evidence is unclear or conflicting, but this is what the Work Group recommends.” The guidelines state that, on the basis of current evidence, it is the Work Group's opinion that assessmen...
Forward-Looking Statements This Quarterly Report contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements other than statements of historical facts contained in this Quarterly Report, including statem...
(Bush 1991; Almen 1994) Pre-existing activation of the complement pathway may increase the chance of an anaphylactoid reaction, meaning it is more likely to occur in sicker patients. (Bush 1991) The underlying pathophysiology probably shares multiple mechanisms with the non-anaphylactoid vasodilation ...
The difference is primarily owing to the rarity of NTRK gene fusions, meaning that a large number of patients need to be tested to identify the few patients that are eligible for entrectinib treatment (0.29%). This means that few patients experience QALY gains from NTRK testing (only the...
Meaning: These findings suggest that first-line FCH PET/CT can replace MIBI SPECT/CT for imaging-guided surgery in patients with PHPT. This randomized clinical trial compares first-line F18-choline (FCH) positron emission tomographic (PET)/computed tomographic (CT) scan vs multiplex...
Despite the lower proportional activity of [68 Ga]Ga-DOTA-TOC in PET/MRI, it detected 14.6% more lesions than PET/CT, meaning that the radiation to be administered in PET/MRI could be adjusted downwards in the future, without affecting its diagnostic performance. Also, the absence of ...
HUTCHMED Limited announces that initial results of the multi-regional clinical trial of fruquintinib, FRESCO-2, will be presented at the upcoming European Society for Medical Oncology Congress 2022, taking place on September 9-13, 2022.
Carisma Therapeutics Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for CT-0525, an ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy intended...